I am an interdisciplinary quantitative scientist, with a demonstrated history of leading regulatory science and product differentiation research in a preclinical CRO setting.Since leaving academia in 2009, I have been supporting the development, regulatory evaluation and product differentiation of complex local therapies through coupling of mechanistic computational models with quantitative experimental benchtop and in vivo models. I have used this paradigm with great effect in the fields of local endovascular drug delivery (drug eluting stents, drug coated balloons), Vessel Preparation, Renal Denervation and Thrombectomy to name a few. I leverage my training in Mathematics, Physics and Biomedical Engineering to help companies accelerate and differentiate their technologies. Starting with my graduate studies I have been fortunate to operate at the interface of academic research and commercial product development. My work deriving computational models of controlled drug delivery from biodegradable devices supported the development of devices for the treatment of gingivitis, mammary tumors, ischemic tissue, drug eluting stents and drug coated balloons. Integrative understanding is achieved through the coupling of interstitial tissue transport, cell uptake and drug pharmacology. Such integrative models are typically computationally intensive due to a dependence on a large number of parameters, some of which are difficult to measure. To overcome these challenges and facilitate experimental verification, I use model reduction techniques to directly connect to experimentally apparent dynamics.Specialties: Product differentiationQuantitative analysis of tissue microanatomy and fluorescent gradientsContinuum models of tissue level heat and drug transport (PDEs) Finite element simulations of convection-reaction-diffusion modelsCell pharmacokinetics of drugs and growth factors (ODEs)Enzyme kineticsAnalytical model reduction and parameter estimation techniquesControlled release from biodegradable matrices